Navigation Links
Halo Pharmaceutical Completes $14.6 Million in Financing from The Provident Bank
Date:4/22/2009

WHIPPANY, N.J., April 22 /PRNewswire/ -- Halo Pharmaceutical, this week announced that it has completed $14.6 million in financing from The Provident Bank to expand its operations.

Headquartered in Whippany, Halo is a privately held full-service, specialty pharmaceutical company. Halo provides state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries.

"Provident is a respected local bank that understands the New Jersey market and the needs of New Jersey's pharmaceutical companies. That's why we chose to go to them for financing," said Mohd Asif, Halo's Chief Financial Officer. "Provident understands that providing the kind of financing that assists local companies helps keep jobs in the Garden State and even helps create jobs here in the future. We look forward to an ongoing close relationship with them."

"We are excited to be working with Halo," said Keith Stinchcomb, Provident vice president and team leader of middle market lending. "At Provident, we focus on building strong relationships with our clients so we can best meet their financial needs. We look forward to continuing to work with Halo as they grow."

Halo's Whippany facilities encompass more than 200,000 sq. ft. and include an array of capabilities. For information about Halo, visit www.halopharma.com or contact Mohd Asif at (973) 428-4013.

For more information about Provident, contact Keith Stinchcomb at (973) 644-5408 or The Provident Bank at 800-448-PROV (7768).

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a specialty pharmaceutical company engaged in pharmaceutical branded product lifecycle management. The company's strategy is to acquire products that are late in their lifecycle and for which lifecycle extension is possible through sustained release formulation development; the addition of appropriate dosage forms and strengths; the development of new indications; and new approaches to promotion of the brands. Halo also offers full service state-of-the-art contract manufacturing in a wide range of dosage forms, formulation and analytical method development from pre-clinical through phase III, and laboratory testing services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic semi solids manufacturing and filling, granulation, blending, tableting, coating and packaging. DEA Schedule 2 to 5 products can also be manufactured and packaged. Halo also has related warehousing and distribution operations. Halo Pharmaceutical is a privately-held company.

About The Provident Bank

With $4.2 billion in deposits, The Provident Bank serves its customers via a network of 82 branches throughout northern and central New Jersey. The Provident Bank is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE: PFS), which reported assets of $6.6 billion as of December 31, 2008.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
2. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
3. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
4. WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category
5. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
6. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
11. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the top ... Living (SHSL) may not share those same worries thanks to a new bundled ... while holding the line on increasing their contributions, including premiums, deductibles and the portions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: